Posted by Michael Wonder on 08 Jun 2021
NICE recommends Tecentriq for first-line NSCLC
7 June 2021 - NICE has recommended Roche’s Tecentriq (atezolizumab) monotherapy for untreated metastatic non-small cell lung cancer.
Tecentriq (atezolizumab) is indicated for adults with metastatic non-small cell lung cancer if their tumours have PD-L1 expression on at least 50% of tumour cells or 10% of tumour-infiltrating immune cells.
